Pharsight

1. List of Invokana drug patents

Application	Filing Date	Opposition Party	Legal Status
EP14194507A	2018-06-06	Galenicum Health S.L.	Patent maintained as amended
EP14194507A	2018-06-05	Generics (UK) Ltd	Patent maintained as amended
EP11721616A	2017-04-13	LEK Pharmaceuticals d.d.	Revoked
EP07850306A	2014-11-12	Galenicum Health S.L.	Patent maintained as amended
EP04771314A	2013-10-16	Galenicum Health S.L.	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (4 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (4 years from now)
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219	JANSSEN PHARMS	Glucopyranoside compound	Apr, 2025 (2 years from now)
US10617668	JANSSEN PHARMS	Pharmaceutical formulations	May, 2031 (8 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Sep 27, 2022

Market Authorisation Date: 29 March, 2013

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL